Todd P. Branning, as Chief Financial Officer, delivers to NeuBase the highest degree of financial knowledge and contributes to the company's medicinal pipeline expansion.
Fremont, CA: “I am excited to join NeuBase at this important time in the Company's growth and contribute my expertise to realize the enormous potential of its platform to treat a wide range of diseases affecting millions of patients that currently have limited or no therapeutic options.” states Mr. Todd P. Branning has been named Chief Financial Officer of NeuBase Therapeutics, a biotechnology platform firm Drugging the Genome to address disease at the base level utilizing a new class of precision genetic therapies. Mr. Branning has over 25 years of expertise in corporate finance and accounting, tax, financial planning and analysis, and investor relations for a number of publicly-traded pharmaceutical businesses.
“Todd brings the highest level of sophistication in finance to NeuBase,” states Dietrich A. Stephan, Ph.D., Founder, CEO, and Chairman of NeuBase. “We are a truly unique genetic medicines platform company with a technology that is specifically designed to directly and precisely drug the double-helix of the human genome and a new therapeutic modality to address root causality across rare and common diseases. Enlightened leadership, creativity, and clarity of thought are essential in developing any new transformational solution. Thus, I am delighted to welcome Todd to the executive team as we begin our next phase of growth with the filing of our first INDs and scaling our therapeutic pipeline.”
Mr. Branning was the CFO of Phathom Pharmaceuticals, Inc., a publicly-traded late clinical-stage biopharmaceutical firm, prior to joining NeuBase. Prior to that, he served as Senior Vice President and Chief Financial Officer of Amneal Pharmaceuticals, Inc., a publicly-traded pharmaceutical firm, where he assisted in the development, leverage, and optimization of infrastructure following a transformational merger.
“I am excited to join NeuBase at this important time in the Companys growth and contribute my expertise to realize the enormous potential of its platform to treat a wide range of diseases affecting millions of patients that currently have limited or no therapeutic options.” adds Mr, Branning.